| Description | Tauroursodeoxycholate (UR 906) is a naturally occurring, highly hydrophilic, tertiary bile acid. Tauroursodeoxycholate is used in studies of primary biliary cirrhosis (PBC), insulin resistance, amyloidosis, cystic fibrosis, cholestasis and amyotrophic lateral sclerosis. |
| In vitro | 方法：过表达 WDR45 突变的 HeLa 细胞用 Tauroursodeoxycholate (200 µM) 处理 24 h，使用 Western Blot 检测靶点蛋白表达水平。结果：使用 Tauroursodeoxycholate 抑制 ER 应激显著降低了表达突变 WDR45 的细胞中 p38 和 LAMP2A 的磷酸化以及 mCherry KFERQ 的点状形成。[1]方法：未分化神经干细胞 NSCs 用 Tauroursodeoxycholate (100 µM) 处理 24 h，通过 BrdU 用 Flow cytometry 检测细胞增殖。结果：Tauroursodeoxycholate 孵育后 BrdU 掺入显著增加。Tauroursodeoxycholate 调节细胞增殖。[2] |
| In vivo | 方法：为检测对糖尿病的作用，将 Tauroursodeoxycholate (300 mg/kg) 腹腔注射给 STZ 诱导糖尿病的 C57BL/6 小鼠，每天一次，持续二十四天。结果：治疗 15 天后，与 STZ 组相比，STZ+Tauroursodeoxycholate 小鼠的血糖降低了 43%。这种减少可能是由于胰岛素血症的增加。[3] |
| Synonyms | Taurolite, 牛磺熊去氧胆酸, Tauroursodeoxycholic Acid, UR 906, Ursodeoxycholyltaurine, TUDCA |
| molecular weight | 499.7 |
| Molecular formula | C26H45NO6S |
| CAS | 14605-22-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | 5% DMSO+95% Saline: 4.5 mg/mL (9.01 mM) DMSO: 6.25 mg/mL (12.51 mM), Sonication is recommended. |
| References | 1. Xiong Q, et al. WDR45 mutation dysregulates iron homeostasis by promoting the chaperone-mediated autophagic degradation of ferritin heavy chain in an ER stress/p38 dependent mechanism. Free Radic Biol Med. 2023 May 20;201:89-97. 2. Xavier JM, et al. Tauroursodeoxycholic acid increases neural stem cell pool and neuronal conversion by regulating mitochondria-cell cycle retrograde signaling. Cell Cycle. 2014;13(22):3576-89. 3. Bronczek GA, et al. The Bile Acid TUDCA Improves Beta-Cell Mass and Reduces Insulin Degradation in Mice With Early-Stage of Type-1 Diabetes. Front Physiol. 2019 May 15;10:561. |